Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development
PR Newswire —
SAN MATEO, Calif., March 5, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year relationship with Alnylam, the leading RNAi therapeutics company. This agreement provides Alnylam access to Helix's continuously growing, deeply phenotyped...